U.S. markets open in 1 hour 36 minutes

Taiwan Liposome Company, Ltd. (TLC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
6.54+0.43 (+7.04%)
At close: 4:00PM EDT
6.54 0.00 (0.00%)
Pre-Market: 04:00AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close6.11
Open6.24
Bid5.90 x 4000
Ask6.53 x 1400
Day's Range6.24 - 6.55
52 Week Range4.07 - 12.65
Volume130,699
Avg. Volume326,446
Market Cap275.187M
Beta (5Y Monthly)0.93
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) Soars 30.3%: Is Further Upside Left in the Stock?
    Zacks

    Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) Soars 30.3%: Is Further Upside Left in the Stock?

    Taiwan Liposome Company, Ltd. Unsponsored ADR (TLC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

  • TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment
    Benzinga

    TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment

    India's Central Drugs Standard Control Organization has approved Taiwan Liposome Company's (NASDAQ: TLC) marketing application for Amphotericin B Liposome for 50mg Injection for immediate import to aid in the country's emergency of acute liposomal amphotericin B shortage. AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis, a serious fungal infection known as a black fungus. With a high number of COVID-19 infections in India, the number of COVID-19 associated mucormycosis (CAM) cases has also been rising. Yesterday, TLC's subsidiary InspirMed Inc presented data on the potential advantages of inhalable liposome formulations that can be used as prophylaxis and treatment for COVID-19. Price Action: TLC shares are up 27.6% at $6.24 during the premarket session on the last check Tuesday. See more from BenzingaClick here for options trades from BenzingaTaiwan Liposome's Inhalable Liposome Formulations of Antiviral Drugs Show Promise In COVID-19© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Taiwan Liposome's Inhalable Liposome Formulations of Antiviral Drugs Show Promise In COVID-19
    Benzinga

    Taiwan Liposome's Inhalable Liposome Formulations of Antiviral Drugs Show Promise In COVID-19

    InspirMed Inc presented data on the potential advantages of inhalable liposome formulations of antiviral drugs at the International Society for Aerosols in Medicine Congress. InspirMed is a subsidiary of Taiwan Liposome Company (NASDAQ: TLC), specializing in developing inhalable liposome formulation programs for severe acute and chronic pulmonary diseases. Pharmacokinetic studies on inhalable liposomal GS-441524 (ISPM21) and inhalable liposomal hydroxychloroquine (ISPM19) showed significantly higher lung concentrations than their conventional counterparts, giving the candidates the potential as prophylaxis and treatment for COVID-19. GS-441524 is the main plasma metabolite of the antiviral prodrug remdesivir, which is approved in the US for COVID-19. GS-441524 holds several advantages over remdesivir, with better safety and efficacy profiles. Intratracheally administered ISPM21 had a long half-life of 22.8 hours, with significantly higher concentrations (over 200-fold) in the lung and comparable systemic exposure in the plasma than an equal dose of intravenously administered GS-441524 solution. At just 1% of the proposed oral dose of hydroxychloroquine to treat COVID-19, intratracheally administered ISPM19 had a longer half-life (around 2.5-fold) and higher exposure in the lung (~30-fold) than intravenously administered free hydroxychloroquine. ISPM19 nebulized into an aerosol exhibited a lung deposition rate (inhaled dose) of 26.67%. Price Action: TLC shares are up 3.3% at $4.4 during the premarket session on the last check Monday. See more from BenzingaClick here for options trades from BenzingaBristol Myers Unveils More Positive Data On Ulcerative Colitis Candidate ZeposiaNovavax Expands COVID-19 Vaccine Pact In South Korea© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.